Actively Recruiting

All Genders
NCT06727162

The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC

Led by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Updated on 2024-12-10

100

Participants Needed

1

Research Sites

60 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The head and neck squamous cell carcinoma is the sixth most common malignant tumor worldwide. For patients with locally advanced head and neck cancer, neoadjuvant therapy is recommended before surgery, including neoadjuvant chemotherapy and immunotherapy. There is a significant variation in patients' responses to neoadjuvant therapy, with approximately 37%-52% of patients achieving a complete pathological response after neoadjuvant therapy. Current research mainly focuses on the efficacy evaluation of the primary tumor, while there is less research on the treatment efficacy evaluation of cervical lymph nodes. In clinical practice, accurate assessment of the status of cervical lymph nodes after neoadjuvant chemoimmunotherapy in patients with squamous cell carcinoma of the head and neck can directly affect the choice of treatment plan by clinicians, reducing unnecessary neck dissection. In recent years, contrast-enhanced ultrasound has been widely used in the diagnosis of thyroid cancer and other head and neck tumors, as well as in the assessment of the benign and malignant nature of cervical lymph nodes. This study aims to explore the value of contrast-enhanced ultrasound in the assessment of cervical lymph nodes after neoadjuvant chemoimmunotherapy in squamous cell carcinoma of the head and neck, in order to guide clinicians in formulating personalized treatment plans.

CONDITIONS

Official Title

The Value of CEUS in Assessing the Response of Cervical Lymph Nodes After NACI for HNSCC

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histopathologically confirmed head and neck squamous cell carcinoma
  • Received neoadjuvant chemoimmunotherapy
  • Diagnosed with cervical lymph node involvement (cN+) by CT or MRI before treatment
  • Underwent radical surgical treatment plus cervical lymph node dissection at this center
Not Eligible

You will not qualify if you...

  • Did not receive a full course of neoadjuvant therapy
  • History of prior treatment for head and neck cancer
  • Clinical evidence of distant metastasis found during preoperative examination

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Guangzhou, Guangdong, China

Actively Recruiting

Loading map...

Research Team

L

Lin Peiliang, Doctor

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here